This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VectivBio Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Luca Santarelli

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.2yrs
CEO ownership	2.5%
Management average tenure	2.5yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

VectivBio gains on pricing of $125M underwritten offering of ordinary shares

Oct 13

VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock

Jul 01

Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome

Jun 15

CEO

Luca Santarelli (53 yo)

4.2yrs

Tenure

Dr. Luca Santarelli, M.D., is the Founder and Chief Executive Officer of VectivBio Holding AG and has been its Director since May 2019. Dr. Santarelli serves as a Member of Scientific Advisory Board at Cur...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Luca Santarelli	Founder	no data	no data	2.46% $ 26.0m
Claudia D'Augusta	Chief Financial Officer	4.1yrs	no data	0.72% $ 7.7m
Christian Meyer	Chief Operating Officer	2.3yrs	no data	0.56% $ 6.0m
Alain Bernard	Chief Technology Officer	4yrs	no data	0% $ 0
Patrick Malloy	Senior VP of Investor Relations & Strategic Communications	1.3yrs	no data	no data
Scott Applebaum	Chief Legal Officer & Corporate Secretary	1.9yrs	no data	0% $ 0
Michael Steininger	Senior VP & Head of Human Resources	no data	no data	no data
Kevin Harris	Chief Commercial Officer	3.7yrs	no data	0.46% $ 4.9m
Sarah Holland	Chief Business Officer	2.7yrs	no data	0.35% $ 3.7m
Omar Khwaja	Chief Medical Officer	2.2yrs	no data	0% $ 0
Martine Mazzetti	Chief of Staff	no data	no data	no data
Nader Youssef	Senior Vice President of Global Medical Affairs & Patient Partnership	no data	no data	no data

2.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: VECT's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Luca Santarelli	Founder	4.2yrs	no data	2.46% $ 26.0m
Thomas Woiwode	Independent Chairman of the Board	4.2yrs	no data	0.029% $ 310.0k
Paul Rutherford Carter	Independent Director	1.8yrs	no data	0% $ 0
Hans J. G. C. Schikan	Independent Director	4.1yrs	no data	0.11% $ 1.2m
Sandip Kapadia	Independent Director	2.8yrs	no data	0.11% $ 1.2m
Murray Stewart	Independent Director	1.8yrs	no data	0.020% $ 210.8k
Wouter Joustra	Independent Director	less than a year	no data	no data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Board: VECT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

This company listing is no longer active

VectivBio Holding Management

Management criteria checks 1/4

Key information

Recent management updates

VectivBio Holding AG Announces the Resignation of Chahra Louafi from the Board of Directors

Vectivbio Holding AG Appoints Wouter Joustra as Member of the Board of Directors

High number of new directors

High number of new and inexperienced directors

VectivBio Holding AG Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

VectivBio Holding AG, Annual General Meeting, Jun 30, 2022

Recent updates

Price target decreased by 7.6% to US$20.80

VectivBio Holding AG Announces the Resignation of Chahra Louafi from the Board of Directors

Vectivbio Holding AG Appoints Wouter Joustra as Member of the Board of Directors

VectivBio Holding AG Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure

Price target increased to US$23.80

VectivBio Holding AG Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients with Colon-In-Continuity

VectivBio gains on pricing of $125M underwritten offering of ordinary shares

High number of new directors

VectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stock

VectivBio Holding AG announced that it has received $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG announced that it expects to receive $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG announced that it expects to receive $19.999995 million in funding from Forbion Capital Partners B.V.

VectivBio Holding AG Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-Versus-Host Disease

High number of new and inexperienced directors

VectivBio Holding AG Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

VectivBio Holding AG, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

VectivBio Holding AG (NasdaqGS:VECT) completed the acquisition of Comet Therapeutics, Inc.

VectivBio Holding AG (NasdaqGS:VECT) entered into a definitive agreement Comet Therapeutics, Inc from Canaan Management, Inc., Sofinnova Partners SAS, INKEF Netherlands Manager B.V. and Mission BioCapital.

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure

Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age